Premium
The effect of fascin 1 inhibition on head and neck squamous cell carcinoma cells
Author(s) -
Wahab Awais,
Hyytiäinen Aini,
Wahbi Wafa,
Tuomainen Katja,
Tervo Sanni,
ConesaZamora Pablo,
Jauhiainen Laura,
Mäkinen Laura K.,
Paavonen Timo,
ToppilaSalmi Sanna,
Salem Abdelhakim,
Almangush Alhadi,
Salo Tuula,
AlSamadi Ahmed
Publication year - 2021
Publication title -
european journal of oral sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.802
H-Index - 93
eISSN - 1600-0722
pISSN - 0909-8836
DOI - 10.1111/eos.12819
Subject(s) - fascin , head and neck squamous cell carcinoma , cancer research , metastasis , in vivo , medicine , cytotoxic t cell , oncology , in vitro , cancer , cancer cell , head and neck cancer , biology , immunohistochemistry , biochemistry , microbiology and biotechnology
Fascin 1 plays important pro‐metastatic roles in head and neck carcinoma (HNSCC) migration, invasion, and metastasis. However, limited advancement in targeting metastasis remains a major obstacle in improving HNSCC patients’ survival. Therefore, we assessed the therapeutic potential of fascin 1 targeted inhibition and its potential prognostic value in HNSCC patients. Using in vitro and in vivo approaches, we investigated the effect of compound G2, a novel fascin 1 inhibitor, on HNSCC cells migration, invasion, and metastasis. High‐throughput screening (HTS) was used to assess cytotoxic activity of compound G2 alone or combined with irradiation. We also evaluated the prognostic potential of fascin 1 in HNSCC patients. Interestingly, compound G2 reduced carcinoma cells migration and invasion in vitro and inhibited metastasis in vivo. Moreover, HTS revealed a modest cytotoxic activity of the compound G2 on HNSCC cell lines. Irradiation did not synergistically enhance the compound G2‐mediated cytotoxic activity. Survival analyses showed that high fascin 1 immunoexpression, at the tumor invasive front, was associated with cancer‐specific mortality in the advanced stages of HNSCC. Collectively, our findings suggest that fascin 1 represents a promising anti‐metastatic therapeutic target and a useful prognostic marker in patients with HNSCC. Novel anti‐metastatic agents could provide a valuable addition to cancer therapy.